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On June 11, 2009, the World Health
Organization (WHO) declared the
first influenza pandemic since
1968.1 Originally known as the
“swine flu” or novel H1N1, the influenza strain has now been renamed
2009
H1N1
(A/
California/7/2009 (H1N1) virus).
The exact origins of the new strain
remain unknown. However, the first
clinical documentation of infection
in humans occurred in Mexico in
March 2009. The strain most likely
evolved during the 2008-2009 seasonal flu season, resulting from a
triple reassortment. The new virus
contains components from human,
avian, and swine sources.2 The virus is now widespread throughout
the Americas and has extended to
parts of Europe and Asia.3
Transmission and incubation times
appear to be similar to seasonal influenza. 2009 H1N1 is most likely
transmitted through respiratory
droplets. However, viral shedding
in feces has been reported, suggesting a possible fecal-oral transmission. The incubation time appears
to range from 2 to 7 days, similar to
seasonal influenza. Viral shedding
most likely begins 1 day prior to
symptom development and may last
up to 7 days after symptom onset or
until symptoms dissipate. Children,
and severely ill/immunocompromised patients may shed virus for
longer periods of time.2

The virulence of 2009 H1N1 appears
to be less than the Spanish influenza
pandemic of 1918-1919, but similar
to the Asian influenza pandemic of
1957 that killed approximately 2 to 4
million people worldwide. The estimated case fatality ratio is 0.4% with
a range of 0.3-1.5% based on current
reports. Based on the suspected infection rate, deaths could range from 6
to 12 million worldwide.2 As of September 27, 2009 there have been
more than 340,000 laboratory confirmed cases and over 4100 deaths
reported to WHO.3 Additionally,
since that time, 99% of circulated
influenza virus in the United States
has been 2009 H1N1.4
Clinical Features
The clinical symptoms of 2009 H1N1
appear to be similar to seasonal influenza, with the most common symptoms including fever, sore throat,
cough, malaise, headache, vomiting,
and diarrhea. The majority of patients
infected experience a mild course and
typically recover in about 1 week
without medical intervention. However, patients may experience severe
complications, including lower respiratory tract infection, respiratory distress, secondary bacterial infections,
and possibly death. Populations at
high risk for complications from infection are listed in Table 1. In addition to these at risk populations, obesity appears to be a risk factor for
severe disease. Seventy
percent
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(70%) of patients hospitalized with
2009 H1N1 possessed an underlying
risk factor. The risk of hospitalization is greatest in children under 2
years of age.2,4
Early immunization reports suggest
patients previously vaccinated repeatedly for seasonal influenza and
patients older than 50 years old may
have preexisting antibodies to 2009
H1N1 influenza. These antibodies
are most likely due to crossreactivity with previous seasonal
influenza strains and exposure to
H1N1 circulating prior to 1957.1
Diagnosis and Testing
Clinical symptoms and suspicion of
influenza should drive diagnosis and
treatment. However, multiple tests
are available for testing influenza
with varying degrees of sensitivity
and specificity for 2009 H1N1.5
Currently, the Center for Disease
Control and Prevention (CDC) recommends that diagnostic testing be
prioritized for hospitalized patients
with suspected influenza and in patients for whom a diagnosis of influenza will change treatment, infection control measures or management of contacts. For patients with
mild symptoms of influenza, diagnostic testing is not recommended.5,6
Several influenza diagnostic tests
are available and include rapid influenza diagnostic tests (RIDTs), direct
immunofluorescence assays (DFAs),
real-time reverse transcriptase polymerase chain reaction (rRT-PCR),
and viral culture. RIDTs are widely
available and can detect influenza
virus in 30 minutes or less. However, the sensitivity of these tests for
2009 H1N1 varies from 10 to 70%.
Sensitivity of the RIDTs used at
MUSC is estimated at 30%. However, the specificity of RIDTs is
greater than 95%. Therefore, a negative RIDT does not exclude influenza infection, but a positive RIDT
is highly suspicious of an acute in-
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fection. DFAs can yield results in 2
to 4 hours and have sensitivities for
2009 H1N1 ranging from 47 to
93% and specificities greater than
96%. Viral cultures are highly sensitive and specific. However, results
of viral culture are often not provided in time to aid in clinical management but are important for public health surveillance. rRT-PCR is
the most sensitive and specific diagnostic test for 2009 H1N1, with
results typically being available in 1
to 2 days.5,6

According to the MUSC Microbiology Lab, the rRT-PCR will be
available in October or November.
Results will be reported as A:H1
seasonal flu, A:H3 seasonal flu, or
A:nontypeable. A:nontypeable corresponds to 2009 H1N1 influenza.
If a patient has an unusual presentation or dies, isolates will be sent to
the Department of Health and Environmental Control (DHEC) for confirmation.
Treatment
Most patients infected with 2009
H1N1 experience uncomplicated
illness and do not require antiviral
therapy or hospitalization. Supportive care in these patients involves
antipyretic use and fluid rehydration. Salicylates should not be used
in patients under the age of 18 due
to the risk of Reye’s syndrome.4,7
However, for patients with severe
infection or in patients at high risk
for complications, antiviral therapy
and hospitalization may be warranted.
Supplemental
oxygen

should be given if hypoxemia occurs
with goal oxygen saturations greater
than 90% or possibly higher in certain clinical situations, including
pregnancy.
Antibiotic
therapy
should not be used unless concern
for bacterial pneumonia exists. If
bacterial pneumonia is suspected,
treatment should follow community
or hospital-acquired pneumonia
guidelines.7
As of September 2009, 99% of
circulating 2009 H1N1 virus
was susceptible to both oseltamivir
and zanamivir, but resistant to rimantadine and amantadine. Oseltamivir resistance is high among
seasonal H1N1 influenza. However,
since April 2009, seasonal H1N1
infections have been few in comparison with 2009 H1N1 in the
United States. Therefore, CDC recommends treatment with either oseltamivir or zanamivir. If seasonal
H1N1 becomes more prominent,
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treatment with zanamivir or a combination of oseltamivir and rimantidine
or amantidine may be warranted.4
CDC recommends treatment for all
hospitalized patients with confirmed,
probable or suspected 2009 H1N1 or
seasonal influenza. Treatment should
be initiated as quickly as possible if
influenza infection is suspected.
Antivirals have been shown to be
most effective if initiated within the
first 48 hours of symptom onset and
may decrease mortality and hospital
duration. CDC recommends treating
for 5 days. However, longer treatment may be warranted for patients
with severe infections. Some experts
have recommended using higher
doses for severe illness although no
data exists to prove increased effectiveness. FDA recently authorized an
Emergency Use Authorization (EUA)
for the use of oseltamivir in children
under the age of 1 year. Both agebased and weight-based dosing have
been advocated for this patient population and are included in Table 2.
The recommended dosing for older
children and adults are included in
Table 3.4
Prevention
Standard infection control measures
should be implemented for hospitalized patients with confirmed or suspected 2009 H1N1 infection. Patients
should be placed on droplet precautions and proper hand hygiene should
be followed.2,7 CDC recommends
against the standard use of antiviral
chemoprophylaxis. However, chemoprophylaxis can be considered in patients at high risk for complications
with exposure to a close contact with
confirmed or suspected 2009 H1N1
or for health care personnel with unprotected exposure to 2009 H1N1.
For antiviral chemoprophylaxis, oseltamivir or zanamivir is recommended. However, the few reported
cases of 2009 H1N1 strains found to
be resistant to oseltamivir typically
developed in patients who became ill
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after receiving chemoprophylaxis,
oseltamivir or zanamivir is recommended. However, the few reported
cases of 2009 H1N1 strains found
to be resistant to oseltamivir typically developed in patients who
became ill after receiving chemoprophylaxis with oseltamivir. Because of the risk for resistance development, the use of early treatment is an alternative to chemoprophylaxis after a suspected exposure.4
Vaccinations have been recently
developed and approved by FDA.
Originally, it was believed two
doses of the vaccine would be required due to the lack of previous
exposure. However, the preliminary
reports of a recent vaccine study in
healthy adults aged 18 to 64
showed a profound immunogenic
response to 1 dose of a monovalent,
inactivated vaccine.1 These results
are promising, but further studies
are needed to determine safety and
efficacy in children and adults with
underlying medical problems. Additionally, there is some new information from Sanofi-Pasteur, a
manufacturer of the H1N1 vaccine,
that suggest that children under the
age of 10 may need 2 injections of
the vaccine to get full protection.8
The ability of vaccine production to
meet the demands for both pediatric
and adult immunizations remains an
immense obstacle to universal vaccination.9
Conclusion
2009 H1N1 influenza poses a new
threat to the world of healthcare.
However, many aspects of the
strain are similar to seasonal influenza. Through judicious infection
control measures, appropriate antiviral usage, and a massive vaccination program, extensive morbidity
and mortality can be avoided. A
multidisciplinary effort is needed to
ensure both patient and employee
well-being. (see page 4 for tables)

Preliminary Data Show
that Asthma Leads H1N1
Hospitalization Risk
October 15, 2009: Preliminary
data from a CDC survey of patients
hospitalized with 2009 H1N1 influenza virus infection have revealed
that those with asthma and other
underlying health conditions are at
an increased risk for serious complications from the flu.
In adults, the most common underlying conditions associated with
hospitalization were asthma and
chronic lung disease. Twenty-six
percent (26%) of the adults who
were hospitalized had asthma. Ten
percent (10%) had diabetes, 8%
had other chronic lung disease besides asthma, 7.6% had immunosuppressive conditions, and 6.1%
were pregnant.
Approximately 55% of adults hospitalized had at least 1 comorbid
condition that may have worsened
their flu course. Surveillance data
came from CDC surveillance
“hotspots.” Information was compiled from 1400 adults and more
than 500 children in 10 states who
were hospitalized between April
2009 and the end of August.
According to preliminary data in
hospitalized children, many of
those patients had asthma, other
chronic lung disease, neurological
or neuromuscular diseases, sickle
cell anemia, or other blood disorders.
CDC is still analyzing the data and
has not yet classified risks for very
young children, those who may be
at high risk for complications from
the flu, or very obese people who
may be more at risk.
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Table 1: Populations at Risk for 2009 H1N1 Complications
−
−
−
−
−
−

Children younger than 2 years old
Persons aged 65 years or older
Pregnant women
Persons of any age with chronic pulmonary (including asthma), cardiovascular (except hypertension), renal,
hepatic, hematological, or metabolic disorders (including diabetes)
Immunocompromised patients
Patients younger than 19 years of age who are receiving long-term aspirin therapy

Table 2: Oseltamivir Dosing Recommendations for Children < 1 Year of Age
Age-Based

Treatment Dose for 5 Days

Prophylaxis Dose for 10 Days

< 3 months

12 mg PO twice daily

Not recommended unless critical situation

3 to 5 months

20 mg PO twice daily

20 mg PO once daily

6 to 11 months

25 mg PO twice daily

25 mg PO once daily

Weight-Based

Treatment Dose for 5 Days

Prophylaxis Dose for 10 Days

3.5 mg/kg/dose PO
twice daily
3.0 mg/kg/dose PO
twice daily

≥ 9 months
< 9 months

3.5 mg/kg PO once daily
3.0 mg/kg PO once daily

Table 3: Antiviral Dosing Recommendations for Adults/Children > 1 Year of Age
Medication

Treatment
(5 Days)

Chemoprophylaxis
(10 Days)

Oseltamivir
Adults
75 mg PO twice daily

75 mg PO once daily

Children ≥ 12 months
≤ 15 kg

30 mg PO twice daily

30 mg PO once daily

>15 kg to 23 kg

45 mg PO twice daily

45 mg PO once daily

>23 kg to 40 kg

60 mg PO twice daily

> 40 kg

75 mg PO twice daily

60 mg PO once daily
75 mg PO once daily

Zanamivir
Adults
10 mg (two 5 mg inhalations)
twice daily

10 mg (two 5 mg inhalations)
once daily

Children (≥ 7 years for treatment, ≥ 5 years for chemoprophylaxis)
10 mg (two 5 mg inhalations)
twice daily

10 mg (two 5 mg inhalations)
once daily
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Update: MUSC Influenza Vaccine Shortage
The ordered amount of seasonal influenza vaccine was significantly reduced due to various factors. Therefore, the original plans to provide vaccine to all patients and employees wishing to be vaccinated has been adjusted.
Ambulatory Patients: For patients scheduled in MUSC-MC clinics the following populations are eligible for influenza
vaccination. If a patient does NOT meet the below criteria, please encourage them to receive their vaccine elsewhere:
− Women who will be pregnant during influenza season.
− Anyone with a weakened immune system due to: HIV/AIDS or other diseases affecting the immune system; longterm treatment with drugs such as steroids; cancer treatment with x-rays or drugs
− Anyone with certain muscle or nerve disorders (such as seizure disorders or cerebral palsy) that can lead to
breathing or swallowing problems.
− Anyone 6 months through 18 years of age on long-term aspirin treatment (they could develop Reye Syndrome if
they got influenza).
− Anyone with long-term health problems with: heart disease; kidney disease; liver disease; lung disease; metabolic disease, such as diabetes; asthma; anemia, and other blood disorders
Inpatients: All inpatients should be screened for seasonal flu vaccine. The inpatient order form is being modified to
take into account the previously mentioned high-priority patients. A portion of our flu vaccine has been reserved for
them.
Staff: Out of the current supply, we have allocated as much vaccine as possible for staff, while still meeting patient
needs. Hospital Leadership is determining the priority groups and the timeline for vaccination based on patient populations served and providers critical to the operations of the hospital. We encourage staff who wish to obtain the seasonal
influenza vaccine sooner to visit their Primary Care Physician or local pharmacy (see page 6).
All employee tent events for October have been cancelled. We are working with our distributors and manufacturers to
obtain more vaccine. If adequate future shipments are received, employee events will be rescheduled.

Did You Know…New USP Standards for Heparin Products Will
Result in Decreased Potency (FDA Alert):
To ensure the quality of heparin and to guard against potential contamination, the United States Pharmacopoeia (USP), a
nonprofit standards-setting organization, adopted new manufacturing controls for heparin. These changes include a
modification of the reference standard for the drug’s unit dose.
Manufacturers in the United States label the amount of heparin included in their products based on USP standards. The
changes adopted by the USP for the heparin unit dose match the World Health Organization’s International Standard (IS)
unit dose definition that has been in use in Europe for many years. The revised USP reference standard and unit definition for heparin is about 10% less potent than the former USP unit.
Manufacturers for the U.S. market have begun to make heparin using the new USP standard. While the USP manufacturing controls take effect Oct. 1 for production, the FDA has asked that they not ship this new product to customers until
Oct. 8, 2009, or later. The delay will give health care providers and facilities time to learn about the changes and to make
adjustments to their pharmacy procedures and dosing practices. Four companies market heparin in the United States:
APP, the largest manufacturer, markets heparin in vials; Hospira markets heparin in intravenous bags, vials, and syringes; Baxter markets heparin in intravenous bags; and B. Braun markets heparin in intravenous bags. The FDA has
asked that all manufacturers identify their new products to help pharmacies and health care professionals differentiate
them from the former products.
At this time it is believed that subcutaneous dosing will not be clinically affected For treatment bolus and continuous
infusions, increased monitoring may be required. The Department of Pharmacy Services will be monitoring this heparin
issue closely. Guidelines and recommendations will be developed and disseminated in the near future.
FDA Alert to Health Care Professionals: http://www.fda.gov//Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm184502.htm
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LOCAL PHARMACIES OFFERING FLU SHOTS
Pharmacy
CVS

Contact
Information
www.cvs.com
1-888-FLU SHOT
Call or go to the website for more dates
and locations

Upcoming Dates
Monday, 10/19/2009
10:00 AM - 02:00 PM
640 Long Point Rd., Mt. Pleasant
Phone: 843-881-5644

Price
$35.00

Wednesday, 10/21/2009
10:00 AM - 02:00 PM
1) 10599 Dorchester Rd., Summerville
(Intersection of Highway 61)
Phone: 843-871-7701
2) 431 St. James Ave., Goose Creek
Phone: 843-572-2606

Walgreen’s

www.walgreens.com
Call individual store
for Most are offering
shots everyday.

Everyday
10:00 AM – 4:00 PM

$24.99
(regular flu shot)

1810 Hwy 17 - North
(US Hwy 17 & James Nelson), Mount Pleasant
Phone: 843-388-2585

$29.99 (thimerosal/
mercury-free flu shots )
$29.99 (Live attenuated flu
vaccine nasal spray)

Publix

www.publix.com
1-877-FLU-8100

Rite Aid

www.riteaid.com

10/27/2009, 11/05/2009, 11/16/2009
10:00 AM- 2:00 PM
1401 Sam Rittenberg Blvd., Charleston
Phone: 843-852-3350

$25

Call for an immunization appointment

$30

334 East Bay Street, Suite D
Charleston
Phone: (843) 723-0263

Bi-Lo

www.bilo.com

10/27/2009
10:00 AM - 2:00 PM
3125 Bees Ferry Road, Charleston
Phone: 843-766-3360
10/29/2009
10:00 AM - 2:00 PM
1200 Sam Rittenburg Blvd., Charleston
Phone: 843-573-4776

$27 (with BiLo Bonus
Card)
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FORMULARY UPDATE FOR SEPTEMBER 2009
In September 2009, the Pharmacy
and Therapeutics Committee approved the actions listed below. The
formulary effective date was October
15, 2009.
ADDED WITH RESTRICTION
Clevidipine (Cleviprex®)
Clevidipine is a new dihydropyridine
IV calcium channel blocker that is
short-acting and vasoselective. It was
added to the formulary with restrictions to the critical care areas (ie,
ICUs, ORs, ED) and the Interventional Radiology area (must be monitored by Anesthesia). Safety concerns
with clevidipine include its contraindications in patients with soy or eggallergies. Since the product contains
lipids, the bottle must be changed
every
4 hours to avoid microbial
growth.
200-mg/20-mL vials

ADDED
Esomeprazole (Nexium®)
Esomeprazole was determined to be
an effective alternative to other available proton pump inhibitors (PPI)
and added to the formulary as the
primary PPI for all patient populations (ie, adult, pediatric, neonate).
Therefore, all other PPIs
(pantoprazole, omeprazole**, and
lansoprazole) will be removed
from the formulary.
** Except for extemporaneous suspension (for use in pts < 10 kg)
20- and 40-mg capsules; 10-, 20-, and
40-mg oral suspension packets;
20-and 40-mg vials
TO REMAIN ON FORMULARY:

Omeprazole (Prilosec®)
extemporaneous suspension
Until extended stability data can be
obtained for esomeprazole suspension, omeprazole suspension will be
available for patients less than 10 kg.
2-mg/mL extemporaneous
suspension

CHANGE IN RESTRICTION
Buprenorphine/Naloxone
(Suboxone®)
Due to the federal requirements for
initiation of opioid-dependence treatment, the ordering of buprenorphine/
naloxone was restricted to physicians
authorized by the Substance Abuse
and Mental Health Services Administration. However, in patients stabilized on treatment and admitted to the
hospital for other reasons, the federal
restrictions do not apply. Therefore,
the restriction will now state that prescribing be limited to the following:
− IOP physicians initiating/
maintaining treatment for opioid
dependence: must be authorized by
the Substance Abuse and Mental
Health Services Administration.
− Patients that are stabilized on
maintenance treatment and are
admitted to a non-IOP service: any
inpatient provider may prescribe;
however, treatment and dose
should be verified with the outpatient provider.

NOT ADDED

Methylnaltrexone (Relistor®)
Methylnaltrexone is a peripherallyacting mu-opioid receptor antagonist
that acts in the gastrointestinal tract.
Methylnaltrexone has shown efficacy
at providing relief from opioid induced constipation in patients suffering from advanced illness in palliative care settings. It has not been
evaluated for efficacy and safety in
any other patient populations. The
medication has minimal safety concerns, as it has been demonstrated to
have a mild side effect profile.
Methylnaltrexone is considered a
last-line therapy in patients with advanced illness and suffering from
opioid-induced constipation unresponsive to stool softeners or stimulant laxatives, mainly due to its
prohibitive costs.

LINE EXTENSIONS

▪ Amylase/lipase/protease (Creon®)
6,000- 12,000-, and 24,000-unit
capsules

DELETIONS

▪ Amylase/lipase/protease(Creon®):
5000-, 10,000-, and 20,000-unit
capsules
▪ Ondansetron (Zofran®)
24-mg tablets
▪ Carnation Good Start
− Formula for the Level 1 Nursery
will return to the previous
method of alternating the Ross
and Mead Johnson products.
CHARTS, GUIDELINES, AND
ORDER FORMS
Metformin Order Entry Hard Stop
Based on recommendations from the
Institute for Safe Medication Practices (ISMP) visit, the Pharmacy
Practice Committee has developed an
order entry hard stop for metformin.
This stop will not allow the pharmacist to enter any metformin order on
patients with an elevated serum
creatinine concentration (≥ 1.4 mg/dL
– females; ≥ 1.5 mg/dL – males). Details and education will be provided
prior to the implementation date
(TBD).
Intravenous to Oral Automatic Conversion Program
Pre-printed stickers will be placed in
the orders and progress notes sections
of the patient chart when a patient
and medication meet pre-specified
inclusion criteria in the protocol. Prescribers are given the option to not
participate in this program for any
given order. Critically ill patients in
the ICUs will not be eligible for this
program. The policy and protocol
requires Medical Executive Committee approval.

